|
![]() |
SustivaThis page contains recent news articles, when available, and an overview of Sustiva but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Sustiva (when available) Efavirenz (dideoxyinosine, ddI) is an oral nucleoside reverse transcriptase inhibitor (NRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine. Currently, the CDC recommends that Efavirenz be given as part of a three-drug regimen that includes another nucleoside reverse transcriptase inhibitor (e.g., lamivudine, stavudine, zidovudine) and a protease inhibitor or efavirenz when treating HIV infection. For use in combination treatment of HIV infection (AIDS) Mechanism Of Action: Similar to zidovudine, Efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of Efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of Efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated Efavirenz, this action may nevertheless account for some of the drug's toxicity. News Articles on Efavirenz Bristol-Myers spent $809K lobbying gov't in 2Q - Aug 24, 2009 Bristol-Myers sells Atripla and Sustiva for HIV infection. Bristol-Myers also lobbied against the government negotiating discounts for drugs sold to seniors Forbes Cipla receives USFDA nod for Efavirenz - Aug 5, 2009 Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral Myiris.com Detectable HIV Levels Don't Necessarily Increase the Risk of ... - Aug 25, 2009 Roughly half of those on treatment were taking a regimen that included efavirenz (found in Sustiva and Atripla), which can affect cognitive function in some AIDSmeds.com HIV/AIDS Treatment News 5 Stocks Making Cash - Aug 12, 2009 A combination of Gilead's Truvada and Bristol-Myers Squibb's (NYSE: BMY) Sustiva, the antiretroviral Atripla is the most prescribed treatment for HIV, Motley Fool When progress comes at a price… - Aug 13, 2009 In both cases the writers compared the results of a “conventionalâ€? first line treatment – of which the third component was either Efavirenz (Sustiva®) or Destination Santé More evidence of bone loss with HIV therapy, more confusion over ... - Aug 13, 2009 Participants were randomised to receive either efavirenz (Sustiva, also marketed as Stocrin) or Kaletra along with AZT plus 3TC (lamivudine, Epivir). Aidsmap Matrix Labs gets tentative USDFA nod for HIV drugs - Aug 14, 2009 Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is prescribed for the treatment of a human TopNews Sida : l'antirétroviral raltegravir sera t-il en première ligne ? - Aug 12, 2009 ...d'un traitement de première ligne « conventionnel » - dont le troisième composant était soit l'efavirenz (Sustiva®) soit le raltegravir (Isentress®). Futura Sciences Merck & Co: dosing regime may hinder Isentress uptake - 14 Jul 2009 STARTMRK study in which the safety and efficacy of Isentress was compared to leading first-line agent Sustiva (efavirenz) in this patient population. Trading Markets (press release) ä¸ç§‘å?ˆè‡£ï¼šé¹?欣集团强势入主 资本整å?ˆå¤§å¹•å¼€å?¯ - 14 Jul 2009 ...å…¬å?¸ä¸»è¦?产å“?02A是一ç§?环丙基乙炔化å?ˆç‰©ï¼Œè¯¥äº§å“?是生产特效抗艾滋病è?¯ç‰©Sustivaçš„é‡?è¦?ä¸é—´ä½“ï¼Œå› è€Œå…·å¤‡æŠ—è‰¾æ»‹ç—…æ¦‚å¿µã€‚ç›®å‰?,艾滋病在亚洲和ä¸å›½é€?æ¥æµ?行并呈现快速上å?‡ 凤凰网 Merck HIV drug Isentress gets full US approval - Jul 9, 2009 The approval was based on a 48-week study comparing patients who took Isentress with patients who took another HIV drug, Sustiva. Both groups also took two Forbes Isentress Gets FDA Approval for Treatment Newbies - Jul 10, 2009 The approval was based on 48 week data from the STARTMRK study comparing Isentress and Truvada (tenofovir plus emtricitabine) with Sustiva (efavirenz) and AIDSmeds.com HIV/AIDS Treatment News Stepped Dosing Lessens Neuropsychiatric Effects of Efavirenz - Jul 6, 2009 NJ, July 6 -- A stepwise dosing schedule eases the neuropsychiatric side effects of the HIV drug efavirenz (Sustiva), a randomized trial showed. MedPage Today MediaVest Wins $400 Million Bristol-Myers Squibb Account - Jun 30, 2009 Some of the pharma giant's biggest selling brands include Plavix, Abilify, Reyataz and Sustiva. This marks the second time in as many months that MediaVest AdAge.com (subscription) Anti-HIV and anti-cancer drugs derived from Borneo rainforest ... - Jun 28, 2009 Approved NNRTIs include Viramune® (nevirapine) from Boehringer Ingelheim, Sustiva® (efavirenz) from Bristol-Myers Squibb, and Rescriptor® (delavirdine) from Mongabay.com BMY -10 Companies With Ironclad Balance Sheets - Jun 28, 2009 The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, TransWorldNews (press release) VAOIG: VA PHARMACY INVENTORY CONTROL NON-EXISTENT - Jun 23, 2009 Four of these drugs—Sustiva, Zyprexa, Ultram, and Levitra—are considered at increased risk for diversion. We also included the anti-clotting drug Plavix in VA Watchdog dot Org Viagra rivals add hours of hope for men - $1.15 per PILL - Jun 30, 2009 ...darunavir (Prezista), efavirenz (Sustiva), nevirapine (Viramune), indinavir (Crixivan), saquinavir (Invirase, Fortovase), lopinavir/ritonavir (Kaletra), Toute la Poésie FUNDVIEW-Franklin fund sees opportunity in cheap biotechs - Jul 6, 2009 Sales of the newer Atripla, which combines Truvada with Bristol-Myers Squibb Co's Sustiva into a single pill, jumped 57 percent in the same period. Forbes Ciencia y tecnologÃa del 3 de julio - Jul 2, 2009 El medicamento, bautizado Atripla, combina los antirretrovirales efavirenz (comercializado con el nombre de Sustiva), emtricitabina (Emtriva) y tenofovir Costa Rica Hoy 疫苗生产上市公å?¸ç›¸å…³åˆ†æž? - Jun 18, 2009 ...ä¸ç§‘å?ˆè‡£(资讯行情论å?›)(600490):公å?¸ä¸»è¦?产å“?02A是一ç§?环丙基乙炔化å?ˆç‰©ï¼Œè¯¥äº§å“?是生产特效抗艾滋病è?¯ç‰©Sustivaçš„é‡?è¦?ä¸é—´ä½“。245化å¦å??称为å?«æ°Ÿè‹¯ç”²é…¸ï¼Œæ˜¯ç”Ÿäº§ä¸€ç±» 阿里巴巴 Gilead Initiates Phase II Clinical Trial Of Integrase-Based ... - 20 Apr 2009 Atripla contains the components Truvada (emtricitabine and tenofovir disoproxil fumarate) and Sustiva (efavirenz), co-formulated as a single tablet. Medical News Today (press release) Gilead initiiert Phase II klinischer Studie zur HIV-Behandlung ... - 20 Apr 2009 Atripla enthält die Komponenten Truvada (Emtricitabin und Tenofovir-Disoproxil-Fumarat) und Sustiva (Efavirenz) in einer Formulierung als Einzeltablette. Business Wire (press release) DEALWATCH: Dull Pharma JV May Become Alluring Spin-Off, Sale - Apr 16, 2009 ...(BMY) has two big HIV drugs, Reyataz and Sustiva, which together generated 2008 sales equal to the JV. And importantly, Gilead and Bristol's HIV products Wall Street Journal Drug to Battle AIDs Abused for Pleasure - Apr 7, 2009 Efavirenz is a prescription drug with the brand names of Sustiva and Stocrins. It is used as part of an antiviral cocktail for patients with HIV and AIDS. Health Jackal A Boon For HIV Drugs? - Apr 9, 2009 Earlier use of antiviral drugs like Viread, Sustiva and Combivir would boost sales for their makers. The biggest winner would likely be Foster City, Calif. Forbes Bone loss during HIV treatment most associated with protease ... - Apr 17, 2009 The prescribed NNRTIs were either efavirenz (Sustiva) or nevirapine (Viramune). With the exception of d4T and ddC, all the licensed NRTIs were available for Aidsmap Gilead Initiates Phase II Clinical Trial of Integrase-Based ... - Apr 17, 2009 The most significant adverse events observed in patients treated with Sustiva are nervous system symptoms, psychiatric symptoms and rash. PR-Inside.com (Pressemitteilung) Gilead initie un essai clinique de Phase II avec un régime ... - Apr 19, 2009 L'Atripla contient les composants Truvada (emtricitabine et fumarate de ténofovir disoproxil) et Sustiva (éfavirenz), en formule commune dans un comprimé Euroinvestor Bristol Names New President, COO - Mar 3, 2009 ...fourth-quarter earnings in January, attributable to the sale of its ImClone stake and to sales of key drugs, including Plavix, HIV drug Sustiva and Abilify. TheStreet.com Ardea Biosciences Reports Progress of Clinical Development ... - Mar 13, 2009 ...which can lead to increased side effects in African-Americans, have been documented with efavirenz (Sustiva(R), Bristol-Myers Squibb). StreetInsider.com (subscription) Pharmacist to help fraud prosecution - Mar 4, 2009 Drugs obtained illegally by Shoemaker and his associates include Sustiva, Norvir, Neupogen, Viramune and Truvada, according to court documents. Gwinnett Daily Post Endothelial dysfunction in Italian cohort caused by HIV, not ... - Mar 8, 2009 Eighty-six per cent of the NNRTI group took efavirenz (Sustiva), and 14% nevirapine (Viramune). The researchers found further evidence of the impact of HIV Aidsmap GSKå½’æ?¥é?é?‡æŠ—艾严冬市场王者地ä½?ä¸?ä¿? - Mar 16, 2009 ...尽管é?žæ ¸è‹·ç±»é€†è½¬å½•酶抑制剂被认为是HIV感染治疗常用的一线治疗方案,但该类è?¯ç‰©ä¸ç¬¬ä¸€ä¸ªè¢«æ‰¹å‡†ä¸Šå¸‚çš„è?¯ç‰©ä¾?å?‘韦仑(efavirenz,Sustiva)å?´å·²ç»?出现了è€?è?¯çš„倾å?‘, 中国医药网 La visibilità degli utili fra le biotecnologie rimane notevole - Feb 24, 2009 L’incremento è stato indotto dalla vendita dei farmaci per il trattamento dell’HIV Truvada e Atripla, una somministrazione unica di Truvada e Sustiva fondionline.it Bristol-Myers Posts Q4 Profit Reversing Year-ago Loss - Update - Jan 27, 2009 The virology portfolio, led by Sustiva and Baraclude also demonstrated consistent growth worldwide, the company said. Global net sales of Plavix for the RTT News, Gilead Sciences Inc. Q4 2008 Earnings Call Transcript - Jan 27, 2009 As Sustiva's one of the preferred third-agents, the combined product of Truvada plus Sustiva, namely Atripla, provides a patient's complete regimen in one Seeking Alpha, Pharma Earnings In Q4 - Healthy Or Ailing? - Jan 25, 2009 Bristol Myers' key products include blood thinner drug Plavix, anti-hypertension drugs Avapro/Avalide, HIV drugs Reyataz and Sustiva, antipsychotic drug Trading Markets (press release), One-a-day regimens mean better adherence for patients starting HIV ... - Jan 29, 2009 ...versus twice-daily abacavir/3TC/AZT (Trizivir); and between d4T (stavudine, Zerit)/3TC (lamivudine, Epivir)/efavirenz (Sustiva), and any other regimen. Aidsmap, US Latinos have more unfavourable metabolic and body fat changes ... - Jan 16, 2009 They also controlled for cumulative time on ten antiretroviral drugs: indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir), efavirenz (Sustiva), Aidsmap, Gilead aiming to put four HIV drugs in one pill - Jan 14, 2009 ...by another of its combination pills Atripla (co-marketed with Bristol-Myers Squibb) which contains tenofovir, emtricitabine and efavirenz (Sustiva). Aidsmap, å“?牌è?¯é™†ç»ä¸“利失效医è?¯å·¨å¤´â€œé‡‘å¼¹â€?攻势ä¸?å‡? - Feb 3, 2009 ...è€Œåœ¨è¿™å‡ ä¸ªé¢†åŸŸé‡Œï¼Œç™¾æ—¶ç¾Žæ–½è´µå®?å?‡æœ‰ç›¸åº”çš„è?¯ç‰©å‡ºå”®ï¼Œå…¶ä¸åŒ…括全ç?ƒç¬¬äºŒå¤§ç•…销è?¯ç‰©æ³¢ç«‹ç»´ï¼ˆPlavix)和Coumadin,抗艾滋病è?¯ç‰©Atriplaå’ŒSustiva æ?œç‹?, Chat avec Christine Katlama sur Yagg: Le dialogue avec les ... - Jan 23, 2009 Mais des amis me disent que le Sustiva rentre dans la composition du comprimé, et peut créer des perturbations d'humeur… Je prends déjà du lithium, yagg.typepad.com, Gleevec wins new FDA indication; Drug shortage could boost Roche's ... - Dec 22, 2008 Report > Aurobindo Pharma won tentative FDA approval to manufacture and market the HIV drug efavirenz, the generic form of branded drugs Sustiva and Stocrin FiercePharma, The New America - Dec 16, 2008 Gilead sells the drug with partner Bristol Myers-Squibb (BMY), which developed Sustiva. Like most drug companies, Gilead's sales come mostly from the US, Investor's Business Daily (subscription) Gilead sues Teva over HIV drug patent - Dec 15, 2008 ...s Sustiva. Truvada sales reached $549.1 million during the third quarter, making up 40 percent of the company's revenue during that period. BusinessWeek Clinic Roundup - Dec 15, 2008 The studies will compare TMC278, given as a once-daily oral tablet, to Sustiva (efavirenz, Bristol-Myers Squibb Co.), when administered with a background TMCnet Citi Upgrades Bristol-Myers Squibb (BMY) to Buy - Dec 10, 2008 Currently marketed drugs in this category would include Abilify for schizophrenia, Reyataz and Sustiva for HIV, Orencia for rheumatoid arthritis, StreetInsider.com (subscription), 12月23æ—¥è¯?券通异动股解密评级å?‚考 - Dec 22, 2008 ...从基本é?¢çœ‹ï¼Œå…¬å?¸ä¸»è¦?产å“?02A是一ç§?环丙基乙炔化å?ˆç‰©ï¼Œè¯¥äº§å“?是生产特效抗艾滋病è?¯ç‰©Sustiva 新浪网, Gileadå°±HIVè?¯å“?专利起诉Teva - Dec 15, 2008 Emtriva与Viread也是三å?ˆä¸€çš„HIV治疗è?¯Atripla,以å?Šç™¾æ—¶ç¾Žæ–½è´µå®?生产的Sustiva 新浪网, 2008-12-11 0:31:58 æ?¥æº?:é?’年人(Qnr.Cn) 作者:Qnr.Cn - Dec 10, 2008 They have ____4____ a single pill that combines three drugs currently on the market.3 Bristol-Myers Squibb sells one of them ____5____ the name of Sustiva é?’年人, Gileadå°±HIVè—¥å“?專利起訴Teva - Dec 15, 2008 Emtriva與Viread也是三å?ˆä¸€çš„HIV治療藥Atripla,以å?Šç™¾æ™‚美施貴寶生產的Sustiva 新浪網, Advierte Ercilia León: Mujeres embarazadas deben hacerse ... - Dec 18, 2008 No obstante, algunos de estos fármacos, incluyendo el efavirenz (Sustiva) y la hidroxiurea, suelen estar contraindicados durante el embarazo debido a un Diario el Tiempo (Venezuela), Celsentri en première intention - Dec 16, 2008 La «non-infériorité virologique» de l'anti-VIH maraviroc (Celsentri, des laboratoires Pfizer) comparé à l'éfavirenz (Sustiva, des laboratoires BMS) est TÊTU, Brand Names/Synonyms: Sustiva is also known by the following brand names and/or synonymsDMP 266; DMP-266; EFV; Efavirenz; Stocrin; Sustiva Drug Category: Sustiva is categorized under the following by the FDA: Anti-HIV Agents; Nonnucleoside Reverse Transcriptase Inhibitors; ATC:J05AG03 Dosage Forms: TABLET, CAPSULE Absorption: Not Available Interactions: -->Interactions for Efavirenz: Efavirenz has been shown in vivo to induce CYP3A4. Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz). In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations. Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug. Therefore, appropriate dose adjustments may be necessary for these drugs. Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations. Drug interactions with SUSTIVA are summarized in Table 5.
Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine. Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine. Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways. Chemical IUPAC Name: 8-chloro-5-(2-cyclopropylethynyl)-5-(trifluoromethyl)-4-oxa-2-azabicyclo[4.4.0]deca-7,9,11-trien-3-one : |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |